Specific Goals. To determine whether treatment with mAb SCH 94.32 promotes functional repair or improvement in conduction in an established animal model of acute spinal cord trauma.
Appears in 2 contracts
Sources: License Agreement (Acorda Therapeutics Inc), License Agreement (Acorda Therapeutics Inc)